Antibodies bispecific. Medical search

Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.

Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).

The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.

Antibodies produced by a single clone of cells.

Immunoglobulins produced in response to VIRAL ANTIGENS.

Immunoglobulins produced in a response to BACTERIAL ANTIGENS.

A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.

A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.

The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.

Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.

Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.

Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.

Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).

Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.

Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.

Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.

Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response.

Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.

Sites on an antigen that interact with specific antibodies.

Antibodies reactive with HIV ANTIGENS.

Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.

The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.

Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.

Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.

Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).

The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.

Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.

Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera.

Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.

Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.

Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.

Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with IMMUNOGLOBULIN Gs. Three subclasses exist: Fc gamma RI (the CD64 antigen, a low affinity receptor), Fc gamma RII (the CD32 antigen, a high affinity receptor), and Fc gamma RIII (the CD16 antigen, a low affinity receptor).

The processes triggered by interactions of ANTIBODIES with their ANTIGENS.

An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.

Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.

The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.

Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes.

A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.

A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.

Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.

Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.

Immunoglobulins produced in a response to FUNGAL ANTIGENS.

A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.

An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN.

The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.

That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.

The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).

Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.

The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.

Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.

Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes.

Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.

An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.

Proteins prepared by recombinant DNA technology.

Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.

Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.

Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).

Established cell cultures that have the potential to propagate indefinitely.

Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.

Antibodies elicited in a different species from which the antigen originated. These antibodies are directed against a wide variety of interspecies-specific antigens, the best known of which are Forssman, Hanganutziu-Deicher (H-D), and Paul-Bunnell (P-B). Incidence of antibodies to these antigens--i.e., the phenomenon of heterophile antibody response--is useful in the serodiagnosis, pathogenesis, and prognosis of infection and latent infectious states as well as in cancer classification.

Antibodies that can catalyze a wide variety of chemical reactions. They are characterized by high substrate specificity and share many mechanistic features with enzymes.

The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.

A cell line derived from cultured tumor cells.

Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.

Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.

A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.

Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.

Experimental transplantation of neoplasms in laboratory animals for research purposes.

Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.

Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.

Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).

A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.

Substances that are recognized by the immune system and induce an immune reaction.

Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.

Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.

A class of organic compounds containing a ring structure made up of more than one kind of atom, usually carbon plus another atom. The ring structure can be aromatic or nonaromatic.

Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.

A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labeled with fluorescein-conjugated anti-immunoglobulin antibody. (From Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)

Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.

Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.

A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.

Methods used for studying the interactions of antibodies with specific regions of protein antigens. Important applications of epitope mapping are found within the area of immunochemistry.

Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.

Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.

In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.

Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.

Histochemical localization of immunoreactive substances using labeled antibodies as reagents.

New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.

Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules.

Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.

The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.

Transplantation between animals of different species.

Substances elaborated by bacteria that have antigenic activity.

Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.

The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.

Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.

The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.

A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.

Elements of limited time intervals, contributing to particular results or situations.

The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.

Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti).

Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.

The sum of the weight of all the atoms in a molecule.

Antibodies obtained from a single clone of cells grown in mice or rats.

Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.

A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.

Substances elaborated by viruses that have antigenic activity.

Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.

Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.

Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.

Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).

The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.

Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)

Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.

A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.

Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.

Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.

Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)

Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.

DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.

Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.

Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.

EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.

A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.

Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains.

Techniques used to demonstrate or measure an immune response, and to identify or measure antigens using antibodies.

A chromatographic technique that utilizes the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)

Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin.

Ribosome inactivating proteins consisting of only the toxic A subunit, which is a polypeptide of around 30 kDa.

A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.

Techniques for removal by adsorption and subsequent elution of a specific antibody or antigen using an immunosorbent containing the homologous antigen or antibody.

Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.

Hoofed mammals with four legs, a big-lipped snout, and a humped back belonging to the family Camelidae.

An encapsulated lymphatic organ through which venous blood filters.

The rate dynamics in chemical or physical systems.

Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. (1/429)

Bispecific monoclonal antibodies (Bi-mAbs) specific for a tumor-associated antigen and the CD3 or CD28 antigen on T lymphocytes represent one of the most successful experimental strategies for the immunotherapy of cancer. We report that the in vivo administration of both alpha-CD3/CD30 and alpha-CD28/CD30 Bi-mAbs results in the specific activation of xenotransplanted, resting human T cells infiltrating the CD30-positive Hodgkin's tumor. Bi-mAb treatment resulted in enhanced expression of cytokines such as interleukin 1beta, interleukin 2, tumor necrosis factor type alpha, and activation markers including Ki-67, CD25, and CD45RO in tumor-infiltrating lymphocytes. This antigen-dependent, local T-cell stimulation led to the activation of the cytolytic machinery in T lymphocytes, determined by the up-regulation of mRNA-encoding perforin and the cytotoxic serine-esterases granzymes A and B. The Bi-mAb-induced generation of CTLs depended on the presence of the CD30 antigen and the combined application of both Bi-mAbs. Our findings suggest that the combined application of T-cell-activating Bi-mAbs is able to achieve a tumor site-specific activation of the T-cell cytolytic machinery in vivo. The fact that these cytotoxic cells do not home in tumor-associated antigen-negative tissue and do not enter circulation might explain our previous observations (C. Renner et al., Blood, 87: 2930-2937, 1996) of a high cure rate in preclinical models even at an advanced stage of disease. (+info)

Dual specificity antibodies using a double-stranded oligonucleotide bridge. (2/429)

The covalent conjugation of oligonucleotides to antibody Fab' fragments was optimized by using oligonucleotides modified with a hexaethylene linker arm bearing three amino groups. One oligonucleotide was coupled to antibody of one specificity and a complementary oligonucleotide to antibody of a second specificity. The antibodies were then allowed to hybridize by base pairing of the complementary nucleotide sequences and the generation of bispecific antibody was analyzed on SDS-PAGE and confirmed using BIAcore analysis. The strategy of complementary oligonucleotide-linked bispecific molecules is not limited to antibodies but is applicable to linking any two molecules of different characteristics. (+info)

An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules. (3/429)

A new, generally applicable procedure is described for the introduction of defined costimulatory molecules into human cancer cells to increase their T-cell stimulatory capacity. The procedure involves infection with Newcastle disease virus to mediate the cell surface binding of costimulatory molecules (e.g., specially designed bispecific antibodies (bsAb)). The modification is independent of tumor cell proliferation and laborious recombinant gene technology and can be applied directly to freshly isolated and gamma-irradiated patient-derived tumor cells as an autologous cancer vaccine. Following the infection of tumor cells with a nonvirulent strain of Newcastle disease virus, the cells are washed and then further modified by coincubation with bsAbs, which attach with one arm to the viral hemagglutinin-neuraminidase (HN) molecule on the infected tumor cells. The second specificity of one bsAb (bs HN x CD28) is directed against CD28 to augment antitumor T-cell responses by selectively channeling positive costimulatory signals via the CD28 pathway. A second bsAb (bs HN x CD3) was produced to deliver T-cell receptor-mediated signals either alone (bsCD3 vaccine) or in combination with anti-CD28 (bsCD3 vaccine plus bsCD28 vaccine). In human T-cell stimulation studies in vitro, the bsCD28 vaccine caused an up-regulation of early (CD69) and late (CD25) T-cell activation markers on CD4 and CD8 T lymphocytes from either normal healthy donors or cancer patients (autologous system) and induced tumor cytostasis in nonmodified bystander tumor cells. In addition, in combination with the bsCD3 vaccine, augmented antitumor cytotoxicity and T-cell proliferative responses were observed. This tumor vaccine modification procedure is highly specific, quick, economic, and has a broad range of clinical applications. (+info)

Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. (4/429)

Two bispecific recombinant molecules, an anti-CD3 x anti-carcinoembryogenic antigen (CEA) diabody and a B7 x anti-CEA fusion protein, were tested for their capacity to specifically activate T cells in the presence of CEA-expressing colon carcinoma cells. T-cell activation by the anti-CD3 x anti-CEA diabody required close contact to CEA-positive cells and resulted in diabody-mediated cytotoxicity against the target cells. Additionally, CD28-mediated costimulation in combination with anti-CD3 x anti-CEA diabodies induced activation of autologous T cells in CEA-positive primary colon carcinoma specimens, as determined by flow cytometry. The high specificity of the bispecific diabody approach could be further enhanced by the use of B7 x anti-CEA fusion proteins because the costimulatory CD28-signaling to the T cells strictly depended on the expression of CEA on the target cells. We demonstrate that displaying engagement sites for the T-cell antigens CD3 and CD28 on the surface of colon carcinoma cells is a suitable way to activate and retarget T cells in a highly tumor-specific manner. For clinical purposes, B7 x anti-tumor-associated antigen (TAA) fusion proteins, which are equally effective but more specific compared with anti-CD28 monoclonal anti-bodies, thus may improve the tumor specificity of anti-CD3 x anti-TAA bispecific antibodies. Furthermore, B7-negative tumors can be converted into B7-positive tumors by B7 x anti-TAA fusion proteins without the need for B7 gene transfer to the malignant cells. (+info)

Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. (5/429)

The "affinity enhancement system," a two-step targeting technique using bispecific antibody and radiolabeled bivalent hapten, has been reported to be useful for carcinoembryonic antigen-expressing tumors. The purpose of this study was to evaluate the efficacy of this method for targeting human small cell lung cancer using an antineural cell adhesion molecule antibody. METHODS: Antineural cell adhesion molecule/antihistamine bispecific antibody NK1NBL1-679 was prepared by coupling an equimolecular quantity of a Fab' fragment of NK1NBL1 to a Fab fragment of antihistamine 679. Athymic mice inoculated with NCI-H69 small cell lung cancer cells expressing neural cell adhesion molecule were administered bispecific antibody and then 48 h later 125I-labeled bivalent histamine hapten. 125I-labeled intact NK1NBL1 was injected into other groups of mice. Biodistributions were examined as a function of time. RESULTS: In mice of the two-step targeting, tumor uptake was 2.5 +/- 0.2, 3.2 +/- 0.4, 6.4 +/- 2.0, 7.2 +/- 2.7, 6.1 +/- 2.1 and 2.2 +/- 0.4 %ID/g at 5, 30 min, 5, 24, 48 and 96 h, and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios were 1.4 +/- 1.1, 10.8 +/- 13.2 and 4.6 +/- 4.7, respectively, at 5 h, whereas 125I-labeled NK1NBL1 showed a tumor uptake of 5.7 +/- 0.4 %ID/g and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios of 0.3 +/- 0.1, 1.1 +/- 0.2 and 0.9 +/- 0.1, respectively, at 5 h. These results were confirmed by autoradiographic studies, which demonstrated clear tumor-to-normal tissue contrast. Dosimetry showed that the affinity enhancement system could enhance the therapeutic potential of the antineural cell adhesion molecule antibody NK1NBL1. CONCLUSION: This two-step targeting method seems promising for the diagnosis and therapy of small cell lung cancer. (+info)

Expression and characterization of bispecific single-chain Fv fragments produced in transgenic plants. (6/429)

We describe the expression of the bispecific antibody biscFv2429 in transgenic suspension culture cells and tobacco plants. biscFv2429 consists of two single-chain antibodies, scFv24 and scFv29, connected by the Trichoderma reesi cellobiohydrolase I linker. biscFv2429 binds two epitopes of tobacco mosaic virus (TMV): the scFv24 domain recognizes neotopes of intact virions, and the scFv29 domain recognizes a cryptotope of the TMV coat protein monomer. biscFv2429 was functionally expressed either in the cytosol (biscFv2429-cyt) or targeted to the apoplast using a murine leader peptide sequence (biscFv2429-apoplast). A third construct contained the C-terminal KDEL sequence for retention in the ER (biscFv2429-KDEL). Levels of cytoplasmic biscFv2429 expression levels were low. The highest levels of antibody expression were for apoplast-targeted biscFv2429-apoplast and ER-retained biscFv2429-KDEL that reached a maximum expression level of 1.65% total soluble protein in transgenic plants. Plant-expressed biscFv2429 retained both epitope specificities, and bispecificity and bivalency were confirmed by ELISA and surface plasmon resonance analysis. This study establishes plant cells as an expression system for bispecific single-chain antibodies for use in medical and biological applications. (+info)

Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. (7/429)

Although bispecific IgG molecules have been successfully applied for antibody-mediated immunotherapy of tumours, applicability is hampered by the difficulties associated with their generation. In the present study, we have used a bispecific single-chain diabody (scDb) directed against carcinoembryonic antigen and Escherichia coli beta-galactosidase as a model to generate bispecific IgG-like antibody molecules. We show that the fusion of this single-chain diabody to the Fc (scDb-Fc) or CH3 (scDb-CH3) region of the human immunoglobulin gamma1 chain results in the expression of dimeric fusion proteins exhibiting four functional antigen binding sites with increased functional affinity. This strategy represents a new and convenient way to generate IgG-like multivalent and bispecific molecules that are efficiently secreted from mammalian cells. (+info)

Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. (8/429)

Bispecific Abs (bsAb) are promising immunological tools for the elimination of tumor cells in minimal residual disease situations. In principle, they target an Ag on tumor cells and recruit one class of effector cell. Because immune reactions in vivo are more complex and are mediated by different classes of effector cell, we argue that conventional bsAb might not yield optimal immune responses at the tumor site. We therefore constructed a bsAb that combines the two potent effector subclasses mouse IgG2a and rat IgG2b. This bispecific molecule not only recruits T cells via its one binding arm, but simultaneously activates FcgammaR+ accessory cells via its Fc region. We demonstrate here that the activation of both T lymphocytes and accessory cells leads to production of immunomodulating cytokines like IL-1beta, IL-2, IL-6, IL-12, and DC-CK1. Thus this new class of bsAb elicits excellent antitumor activity in vitro even without the addition of exogenous IL-2, and therefore represents a totally self-supporting system. (+info)

There are several subtypes of B-cell leukemia, including:

1. Chronic lymphocytic leukemia (CLL): This is the most common type of B-cell leukemia, and it typically affects older adults. CLL is a slow-growing cancer that can progress over time.
2. Acute lymphoblastic leukemia (ALL): This is a fast-growing and aggressive form of B-cell leukemia that can affect people of all ages. ALL is often treated with chemotherapy and sometimes with bone marrow transplantation.
3. Burkitt lymphoma: This is an aggressive form of B-cell leukemia that typically affects older adults in Africa and Asia. Burkitt lymphoma can be treated with chemotherapy and sometimes with bone marrow transplantation.
4. Hairy cell leukemia: This is a rare type of B-cell leukemia that is characterized by the presence of hair-like projections on the surface of cancer cells. Hairy cell leukemia can be treated with chemotherapy and sometimes with bone marrow transplantation.

The diagnosis of B-cell leukemia is based on a combination of physical examination, medical history, laboratory tests, and biopsies. Treatment options for B-cell leukemia include chemotherapy, bone marrow transplantation, and in some cases, targeted therapy with drugs that specifically target cancer cells. The prognosis for B-cell leukemia varies depending on the subtype of the disease and the patient's overall health.

There are several subtypes of lymphoma, B-cell, including:

1. Diffuse large B-cell lymphoma (DLBCL): This is the most common type of B-cell lymphoma and typically affects older adults.
2. Follicular lymphoma: This type of lymphoma grows slowly and often does not require treatment for several years.
3. Marginal zone lymphoma: This type of lymphoma develops in the marginal zone of the spleen or other lymphoid tissues.
4. Hodgkin lymphoma: This is a type of B-cell lymphoma that is characterized by the presence of Reed-Sternberg cells, which are abnormal cells that can be identified under a microscope.

The symptoms of lymphoma, B-cell can vary depending on the subtype and the location of the tumor. Common symptoms include swollen lymph nodes, fatigue, fever, night sweats, and weight loss.

Treatment for lymphoma, B-cell usually involves chemotherapy, which is a type of cancer treatment that uses drugs to kill cancer cells. Radiation therapy may also be used in some cases. In some cases, bone marrow or stem cell transplantation may be recommended.

Prognosis for lymphoma, B-cell depends on the subtype and the stage of the disease at the time of diagnosis. In general, the prognosis is good for patients with early-stage disease, but the cancer can be more difficult to treat if it has spread to other parts of the body.

Prevention of lymphoma, B-cell is not possible, as the exact cause of the disease is not known. However, avoiding exposure to certain risk factors, such as viral infections and pesticides, may help reduce the risk of developing the disease. Early detection and treatment can also improve outcomes for patients with lymphoma, B-cell.

Lymphoma, B-cell is a type of cancer that affects the immune system and can be treated with chemotherapy and other therapies. The prognosis varies depending on the subtype and stage of the disease at diagnosis. Prevention is not possible, but early detection and treatment can improve outcomes for patients with this condition.

Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.

Types of Neoplasms

There are many different types of neoplasms, including:

1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.

Causes and Risk Factors of Neoplasms

The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:

1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.

Signs and Symptoms of Neoplasms

The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:

1. Unusual lumps or swelling
2. Pain
3. Fatigue
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.

Diagnosis and Treatment of Neoplasms

The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.

The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:

1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.

Prevention of Neoplasms

While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:

1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.

It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.

... entry in the public domain NCI Dictionary of Cancer Terms Bispecific+antibodies at the US ... Suurs FV, Lub-de Hooge MN, de Vries EG, de Groot DJ (September 2019). "A review of bispecific antibodies and antibody ... Bispecific antibodies have a wide variety of applications in diagnosis and therapy. BsAbs can be combined with HRPO, can be ... October 2012). "A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model". ...

https://en.wikipedia.org/wiki/Bispecific_monoclonal_antibody

"Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical ... Holmes, David (2011). "Buy Buy Bispecific Antibodies". Nature Reviews Drug Discovery. 10: 798. doi:10.1038/nrd3581. PMID ... "Improving biophysical properties of a bispecific antibody scaffold to aid developability". mAbs. 5 (5): 646-654. doi:10.4161/ ... development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that ...

https://en.wikipedia.org/wiki/Zymeworks

These bispecific monoclonal antibodies are sometimes referred to as mAb2. Antibody Fab region Protein tag Janeway, CA, Jr.; et ... "MAb2 ™Bispecific Monoclonal Antibodies". Archived from the original on 2013-07-08. Retrieved 2013-08-13. (Articles with short ... Fcab fragments can be inserted into a full immunoglobulin by swapping the Fc region, thus obtaining a bispecific antibody (with ... This property allows antibodies to activate the immune system. In IgG, IgA and IgD antibody isotypes, the Fc region is composed ...

https://en.wikipedia.org/wiki/Fragment_crystallizable_region

... and there is extensive research for bispecific antibodies. Applications of bispecific antibodies cover a broad spectrum that ... Brinkmann, Ulrich; Kontermann, Roland E. (2017-02-17). "The making of bispecific antibodies". mAbs. 9 (2): 182-212. doi:10.1080 ... small bivalent and bispecific antibody fragments". Proceedings of the National Academy of Sciences. 90 (14): 6444-6448. Bibcode ... The most common example for multivalent binding are the antibodies, ...

https://en.wikipedia.org/wiki/Protein_engineering

Trifunctional antibodies were the first type of bispecific monoclonal antibodies to be produced. The first concepts date back ... antibody as well as pure mouse and pure rat antibody. The trifunctional antibody is extracted chromatographically with protein ... Chames, P; Baty, D (2009). "Bispecific antibodies for cancer therapy: the light at the end of the tunnel". mAbs. 1 (6): 1-9. ... Choi, BD; et, al.; Bigner, DD; Mehta, AI; Kuan, CT; Sampson, JH (2011). "Bispecific antibodies engage T cells for antitumor ...

https://en.wikipedia.org/wiki/Trifunctional_antibody

The furthest developed of these are bispecific tandem di-scFvs, known as bi-specific T-cell engagers (BiTE antibody constructs ... "Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block ... Kufer, Peter; Lutterbüse, Ralf; Baeuerle, Patrick A. (2004). "A revival of bispecific antibodies" (PDF). Trends in ... Hollinger, Philipp; Prospero, T; Winter, G (July 1993). ""Diabodies": small bivalent and bispecific antibody fragments". ...

https://en.wikipedia.org/wiki/Single-chain_variable_fragment

Bispecific antibodies combine two different antigen binding specificities within one molecule. The bispecific antibodies are ... The most commonly used are the scFv, Fab fragments and bispecific antibodies. scFv is the smallest of the recombinant antibody ... Recombinant antibodies are antibody fragments produced by using recombinant antibody coding genes. They mostly consist of a ... scFv or somatically fused antibodies create a bispecific antibody. The most commonly applied technology to produce recombinant ...

https://en.wikipedia.org/wiki/Recombinant_antibodies

Holliger, Philipp (1994). Multivalent and bispecific antibody fragments from E.coli: new strategies for antibody-based ... Holliger, P.; Prospero, T.; Winter, G. (15 July 1993). ""Diabodies": small bivalent and bispecific antibody fragments". ... Holliger developed a new type of bispecific antibody fragment, called a diabody and worked on elucidating the infection pathway ...

https://en.wikipedia.org/wiki/Philipp_Holliger

Baeuerle, Patrick A.; Reinhardt, Carsten (2009-06-15). "Bispecific T-Cell Engaging Antibodies for Cancer Therapy". Cancer ... and the development of bispecific T-cell engaging antibodies for therapy of cancer. Baeuerle earned his diploma in biology from ... "Bispecific T-cell engaging antibodies for cancer therapy". Cancer Research. 69 (12): 4941-4944. doi:10.1158/0008-5472.CAN-09- ... "Reinventing the Antibody". The Scientist. Retrieved 2017-10-04. Perkel, Jeffrey (2008-08-14). "New Lymphoma Drug Shows Promise ...

https://en.wikipedia.org/wiki/Patrick_A._Baeuerle

The beginning of the pretargeting concept was based on bispecific antibodies which were able to bind a specific target antigen ... Owing to the high molecular weight of antibodies and the Fc domain of the antibody, a slow clearance from the blood and non- ... However, these types of antibodies turned out to be quite troublesome, due to the triggering of the human anti-murine antibody ... "Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy". ...

https://en.wikipedia.org/wiki/Pretargeting_(imaging)

An antibody can be called monospecific if it has specificity for the same antigen or epitope, or bispecific if they have ... antibody Neutralizing antibody Optimer Ligand Secondary antibodies Single-domain antibody Slope spectroscopy Synthetic antibody ... Antibody fragments, such as Fab and nanobodies are not considered as antibody mimetics. Common advantages over antibodies are ... Affimer Anti-mitochondrial antibodies Anti-nuclear antibodies Antibody mimetic Aptamer Colostrum ELISA Humoral immunity ...

https://en.wikipedia.org/wiki/Antibody

31 (4). Guy DG, Uy GL (October 2018). "Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia". Curr Hematol Malig ... Drugs that are a monoclonal antibody, All stub articles, Monoclonal antibody stubs, Monoclonal antibodies). ... Flotetuzumab (INN; development code MGD006) is a bispecific antibody designed for the treatment of acute myeloid leukemia. This ... a focus on monoclonal antibodies and immune checkpoint inhibitors". Curr. Opin. Hematol. 25 (2): 136-145. doi:10.1097/MOH. ...

https://en.wikipedia.org/wiki/Flotetuzumab

Another technology recently developed is the OkapY bispecific antibody technology. MorphoSys' OkapY technology is a new ... bispecific antibody format with the hysicochemical properties to simplify the development and large-scale production of such ... Two antibodies developed by MorphoSys are already approved and marketed. Tafasitamab (MOR208) is a humanized monoclonal ... The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and ...

https://en.wikipedia.org/wiki/MorphoSys

Bispecific Antibody Traps". Journal of the American Chemical Society. 142 (41): 17703-17713. doi:10.1021/jacs.0c08458. ISSN ... antibody-based chemically induced dimerizers (AbCID), antibody-Based PROTACs (AbTAC), antibody targeting a proteolytic ... "Recombinant Antibody Network". recombinant-antibodies.org. Retrieved 15 November 2022. Martinko, Alexander J.; Truillet, ... devoted to generating human recombinant antibodies at a proteome-wide scale using high throughput platforms for antibody phage ...

https://en.wikipedia.org/wiki/James_A._Wells

... (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting ... Drugs that are a monoclonal antibody, Experimental cancer drugs, Monoclonal antibodies, Orphan drugs, All stub articles, ...

https://en.wikipedia.org/wiki/Istiratumab

He received his doctorate in 1992 with a thesis on immunotherapy against tumor cells (bispecific monoclonal antibodies for the ... 12 June 2017). "Elimination of large tumors in mice by mRNA-encoded bispecific antibodies". Nature Medicine. 23 (7): 815-817. ... Antibody Shines in Advanced Gastric Cancer, 5 June 2016, retrieved 26 October 2020 "A Study of Zolbetuximab (IMAB362) Plus ... Ganymed developed the monoclonal antibody Zolbetuximab, for use against esophageal and gastrointestinal cancer. In 2016, after ...

https://en.wikipedia.org/wiki/Uğur_Şahin

... , sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer ... Clinical trial number NCT02609776 for "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With ... August 2020). "Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR ... April 2021). "Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET". J Biol Chem. 296: 100641 ...

https://en.wikipedia.org/wiki/Amivantamab

CD79B The bispecific antibodies have yielded promising results in clinical trials. In April 2009, the bispecific antibody ... Antibody-drug conjugates (ADCs) are antibodies linked to one or more drug molecules. Typically when the ADC meets the target ... Four major antibody types that have been developed are murine, chimeric, humanised and human. Antibodies of each type are ... Initial therapeutic antibodies were murine analogues (suffix -omab). These antibodies have: a short half-life in vivo (due to ...

https://en.wikipedia.org/wiki/Monoclonal_antibody_therapy

Genentech was able to demonstrate in mouse models that the new bispecific antibody was able to reach therapeutic levels in the ... They utilized a mouse bispecific antibody with two active sites performing different functions. One arm had a low-affinity anti ... Researchers at Genentech proposed the creation of a bispecific antibody that could bind the BBB membrane, induce receptor- ... This way, the amount of transported antibody is based on the concentration of antibody on either side of the barrier. The other ...

https://en.wikipedia.org/wiki/Transcytosis

2017-08-24). "Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing". PLOS ONE. 12 (8 ... similar to additional in vitro work using bispecific antibodies performed at Amgen. Some reports have suggested that the ... Fas was first identified using a monoclonal antibody generated by immunizing mice with the FS-7 cell line. Thus, the name Fas ... This event is also mimicked by binding of an agonistic Fas antibody, though some evidence suggests that the apoptotic signal ...

https://en.wikipedia.org/wiki/Fas_receptor

One of them is development of bispecific antibodies such as CD3/CLL-1 antibody. It can recruit unstimulated primary T cells in ... February 2017). "An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia". Blood. 129 (5): 609- ...

https://en.wikipedia.org/wiki/CLEC12A

2014). "Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface". Nature Biotechnology ... designed fusions for bispecific antibodies, and progress toward vaccines. DeLano Award for Computational Biosciences Feynman ...

https://en.wikipedia.org/wiki/Brian_Kuhlman

Nithiyanandam developed a bispecific antibody composed of two different Fab' fragments: one fragment from an anti-oligomeric ... Nithiyanandam's bispecific antibody is conjugated to a quantum dot with MRI and fNIR detection capabilities. Nithiyanandam's in ... vitro studies suggest that the bispecific antibody quantum dot conjugate has little cross-reactivity and could potentially ...

https://en.wikipedia.org/wiki/Krtin_Nithiyanandam

This approach is similar to the one taken in the development of bispecific monoclonal antibodies. In a study, the plasma half- ... Since they are not structurally related to antibodies, they are classified as a type of antibody mimetic. Avimers have been ... Half-life can be increased by binding them to antibodies. A library theoretically containing up to 1023 different A domains ... They have improved heat stability compared with antibodies, but limited plasma half-life because of their smaller size. ...

https://en.wikipedia.org/wiki/Avimer

Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S (Feb 2006). "Use of trifunctional bispecific antibodies to prevent ... Krolick KA, Uhr JW, Slavin S, Vitetta ES (Jun 1982). "In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A ... Herman Waldmann, Slavin was the first to introduce the use of an anti-CD52 monoclonal antibody (CAMPATH-1; Alemtuzumab and ... focusing on the use of activated donor lymphocytes targeted against cancer with monoclonal and bispecific antibodies for ...

https://en.wikipedia.org/wiki/Shimon_Slavin

Engineered antibodies such as single-chain Fv antibodies (sFvs) or bispecific antibodies have been used for targeting and ... An anti-CEA antibody is an antibody against CEA. Such antibodies to CEA are commonly used in immunohistochemistry to identify ... "A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors". Clinical Cancer ... Because even monoclonal antibodies to CEA tend to have some degree of cross-reactivity, occasionally giving false positive ...

https://en.wikipedia.org/wiki/Carcinoembryonic_antigen

"Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen- ... making it a type of bispecific antibody. They are fragments antigen-binding (Fab or Fab') of two different monoclonal ... Development and characterisation of bispecific antibody derivatives for the immunotherapy of CD19-positive leukaemia and ... Bi-specific T-cell engagers employ a similar mechanism of action while being cheaper. Karpovsky, B.; Titus, J. A.; Stephany, D ...

https://en.wikipedia.org/wiki/Chemically_linked_Fab

... comprising bispecific and multispecific monoclonal antibodies. Finally, group 4 assigns the stem -ment for monospecific ... Other antibody parts (such as Fc regions) and antibody mimetics use different naming schemes. For antibodies named until early ... ximab just as does the human/macaque antibody gomiliximab. Purely human antibodies used -u-. Rat/mouse hybrid antibodies can be ... This means that antibodies with the same source and target substems are only distinguished by their prefix. Even antibodies ...

https://en.wikipedia.org/wiki/Nomenclature_of_monoclonal_antibodies

... a bispecific antibody, inhibits tumor progression and angiogenesis". mAbs. 8 (5): 892-904. doi:10.1080/19420862.2016.1171432. ... "Anti-Nogo-A antibodies prevent vascular leakage and act as pro-angiogenic factors following stroke". Scientific Reports. 9 (1 ...

https://en.wikipedia.org/wiki/Angiogenesis

... (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Genentech ... May 2016). "Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A". The New England Journal of Medicine ... a novel factor VIII-mimetic bispecific antibody, in healthy subjects". Blood. 127 (13): 1633-41. doi:10.1182/blood-2015-06- ... Monoclonal antibodies, All stub articles, Monoclonal antibody stubs, Blood and blood forming organ drug stubs). ...

https://en.wikipedia.org/wiki/Emicizumab

The most promising neutralizing agent is a bispecific monoclonal antibody that entered a first-in-human clinical trial in 2019 ... The Ho Lab is funded by two NIH grants to pursue the use of engineered antibodies to purge the viral latent reservoir as a part ... In parallel, Ho's group has also engineered exquisitely potent antibodies that neutralize divergent strains of HIV. ...

https://en.wikipedia.org/wiki/David_Ho

March 2007). "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected ... It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively ... Drugs that are a monoclonal antibody, Breakthrough therapy, Immunology, Monoclonal antibodies for tumors). ... Blinatumomab is a bispecific T-cell engager (BiTE). It enables a patient's T cells to recognize malignant B cells. A molecule ...

https://en.wikipedia.org/wiki/Blinatumomab

There are several mechanisms by which this can be achieved, namely monoclonal antibodies, bispecific antibodies, antibody-drug ... It was shown that antibody-drug conjugates work better than naked antibodies. The reason is that CD22 is rapidly internalized ... Inotuzumab consists of a CD22-targeting immunoglobulin G4 humanized monoclonal antibody conjugated to calicheamicin. The ...

https://en.wikipedia.org/wiki/CD22

... bispecific antibodies technologies, single B cell screening technology), antibody engineering (antibody humanization, affinity ... GenScript ProBio provides solutions for antibody drug development including antibody drug discovery (hybridoma, antibody ... "Duke-NUS, GenScript and A*STAR launch first-in-the-world SARS-CoV-2 serology test to detect neutralising antibodies without ... "GenScript Announces Publication of Clinical Data On New Method for Detecting COVID-19 Neutralizing Antibodies In Nature ...

https://en.wikipedia.org/wiki/GenScript_Biotech

... and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is ... antibodies, and novel antibody-based proteins. The XpressCF+ platform allows for precise incorporation of non-natural amino ... To date, Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, ... internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in ...

https://en.wikipedia.org/wiki/Sutro_Biopharma

... antibodies, bispecific MeSH D12.776.377.715.548.114.143 - antibodies, blocking MeSH D12.776.377.715.548.114.167 - antibodies, ... antibodies MeSH D12.776.377.715.548.114.071 - antibodies, anti-idiotypic MeSH D12.776.377.715.548.114.107 - antibodies, ... antibodies, helminth MeSH D12.776.377.715.548.114.191 - antibodies, heterophile MeSH D12.776.377.715.548.114.224 - antibodies, ... hiv antibodies MeSH D12.776.377.715.548.114.254.150.500 - htlv-i antibodies MeSH D12.776.377.715.548.114.254.150.510 - htlv-ii ...

https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D12.776)

... a monoclonal antibody antagonist of the glucagon receptor for type 2 diabetes (T2DM) REGN4018, a novel MUC16xCD3 bispecific T- ... a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol RN6G, a monoclonal antibody against Beta amyloid for the ... a monoclonal antibody against nerve growth factor for the treatment of pain Ponezumab (codenamed RN1219), a monoclonal antibody ... "REGN4018, a novel MUC16xCD3 bispecific T-cell engager for the treatment of ovarian cancer". "FIH study of an OX40 agonist mAb ...

https://en.wikipedia.org/wiki/Rinat_Neuroscience_Corporation

Lund ME, Howard CB, Thurecht KJ, Campbell DH, Mahler SM, Walsh BJ (December 2020). "A bispecific T cell engager targeting ... GPC1 has been evaluated as a potential target for cancer therapy, including antibody-drug conjugates, CAR-T cell therapy, ... May 2020). "Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)". ... March 2018). "Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 ...

https://en.wikipedia.org/wiki/Glypican_1

... antibodies, bispecific MeSH D12.776.124.486.485.114.143 - antibodies, blocking MeSH D12.776.124.486.485.114.167 - antibodies, ... antibodies, bispecific MeSH D12.776.124.790.651.114.143 - antibodies, blocking MeSH D12.776.124.790.651.114.167 - antibodies, ... antibodies MeSH D12.776.124.486.485.114.071 - antibodies, anti-idiotypic MeSH D12.776.124.486.485.114.089 - antibodies, ... antibodies, helminth MeSH D12.776.124.486.485.114.191 - antibodies, heterophile MeSH D12.776.124.486.485.114.224 - antibodies, ...

https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D12.776.124)

"FDA approves Roche's Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss". Roche ( ... "Phase II data support potential for Roche's novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with ... Faricimab is a 150kDa-sized bispecific antibody whose molecular structure allows a high affinity bond to both vascular ... Faricimab is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor (VEGF), and ...

https://en.wikipedia.org/wiki/Faricimab

... and attachment to bispecific antibodies. All of these delivery systems have been shown to significantly decrease tumor size in ... to lymphoma cells via CD22 and CD38 using bispecific antibodies". British Journal of Cancer. 71 (5): 986-994. doi:10.1038/bjc. ...

https://en.wikipedia.org/wiki/Gelonin

Sun LL (2015). "Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies". Sci Transl Med. 7 ... Kim CH (2013). "Bispecific small molecule-antibody conjugate targeting prostate cancer". PNAS. 110 (44): 17796-17801. Bibcode: ... Frankel SR (2013). "Targeting T cells to tumor cells using bispecific antibodies". Curr Opin Chem Biol. 17 (3): 385-392. doi: ... In addition to antibody fragments, non‐antibody‐based approaches have also been used to direct CAR specificity, usually taking ...

https://en.wikipedia.org/wiki/CAR_T_cell

"Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid ... This company focused on a new class of cancer drugs called ideal monoclonal antibodies and developed zolbetuximab, which is ...

https://en.wikipedia.org/wiki/Özlem_Türeci

In-vitro and in-vivo activity of CIK cells in conjunction with bispecific antibodies, cross-linking cytotoxic effector cells ... "Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells ... "Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: ... Indeed, the engagement of CD16a on CD3+CD56+ cells led to a potent antibody-dependent cell-mediated cytotoxicity (ADCC) both in ...

https://en.wikipedia.org/wiki/Cytokine-induced_killer_cell

... an acronym for bi-specific T-cell engagers, a class of specific modified antibodies BITE Model (Behavior, Information, Thought ...

https://en.wikipedia.org/wiki/Bite_(disambiguation)

Bispecific antibody fragments, such as anti-CD19/CD16, allow the targeting of immunotherapeutic drugs to the cancer cell. Anti- ... These receptors bind to the Fc portion of IgG antibodies, which then activates antibody-dependent cell-mediated cytotoxicity ( ... In addition, CD16 could play a role in antibody-targeting cancer therapies. FcγRIV, a murine homologue of CD16A has been shown ... After binding to ligands such as the conserved section of IgG antibodies, CD16 on human NK cells induce gene transcription of ...

https://en.wikipedia.org/wiki/CD16

Anti-CD20 antibodies are divided into Type I such as rituximab (RTX) and Type II such as obinutuzumab (OBN); they have ... This new system is composed of two nanoconjugates: a) bispecific engager, OBN-MORF1 (OBN conjugated to one morpholino ... Our design enhances the activity of Type II OBN by triggering the apoptosis activation pathways of both types of antibodies. ... This new approach, called "clustered OBN (cOBN)" combines effects of both antibody types resulting in very high apoptotic ...

https://en.wikipedia.org/wiki/Jindřich_Kopeček

However, the efficiency of mAbs is far from optimal, and antibody engineering is actively used to improve the molecules. ... Bispecific antibodies for cancer therapy Patrick Chames et al. Curr Opin Drug Discov Devel. 2009 Mar. ... Current perspectives of bispecific antibody-based immunotherapy. Talac R, Nelson H. Talac R, et al. J Biol Regul Homeost Agents ... Recombinant bispecific antibodies for cellular cancer immunotherapy. Müller D, Kontermann RE. Müller D, et al. Curr Opin Mol ...

https://pubmed.ncbi.nlm.nih.gov/19333873

FDA OKs Bispecific Antibody for Rare Lung Cancer Subtype. - Amivantamab approved for tumors with EGFR exon 20 insertion ... Amivantamab is a bispecific antibody that targets EGFR and mesenchymal-epithelial transition factor pathways. EGFR exon 20 ...

https://www.medpagetoday.com/hematologyoncology/lungcancer/92741

... and therefore attempts have been made to reduce the concentration of these antibodies in the bloodstream of SLE patients. ... High avidity anti-dsDNA IgG antibodies are believed to play an important role in the pathogenesis of the autoimmune disease ... A bispecific dsDNAxmonoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus J Immunol ... It should be possible to test these new AHP for their ability to target and safely remove IgG anti-dsDNA antibodies from the ...

https://pubmed.ncbi.nlm.nih.gov/11223074/?dopt=Abstract

Engineering sequence-specific antibodies (Abs) against phosphotyrosine (pY) motifs embedded in folded polypeptides remains ... Bispecific Antibody Traps Xin X Zhou 1 , Colton J Bracken 1 , Kaihua Zhang 2 , Jie Zhou 1 , Yun Mou 1 , Lei Wang 1 , Yifan ... Targeting Phosphotyrosine in Native Proteins with Conditional, Bispecific Antibody Traps Xin X Zhou et al. J Am Chem Soc. 2020 ... Engineering sequence-specific antibodies (Abs) against phosphotyrosine (pY) motifs embedded in folded polypeptides remains ...

https://www.ncbi.nlm.nih.gov/pubmed/32924468

Merus, which develops bispecific antibody therapeutics to treat cancer patients, and Selexis, which has technologies for ... "Bispecific antibody combinations have potency and targeting advantages that provide the basis for improved anti-cancer ... "With our optimized off-the-shelf CHO media and feeds, we will maximize expression of the bispecific antibody combinations ... Merus and Selexis Receive Grant for Bispecific Antibody Therapeutics. .social-ris-container { display: flex; justify-content: ...

https://www.pharmtech.com/view/merus-and-selexis-receive-grant-bispecific-antibody-therapeutics-0

... portfolio of therapeutic human bispecific antibody candidates, including bispecific antibodies in pre-clinical development ... Merus lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential ... Merus second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia, ... Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies January 4, 2016. Utrecht, The ...

http://baycitycapital.com/portfolio-news/merus-and-gustave-roussy-form-strategic-collaboration-to-develop-innovative-bispecific-antibodies/

Nature Medicine Reports Elimination of Large Tumors in Mice by Messenger RNA-Encoded Bispecific Antibodies ... Bispecific antibodies act by connecting human immune cells to tumor cells for highly efficient killing and have demonstrated ... "Our data show that with low doses of mRNA encoding a bispecific antibody, we get sustained production of RiboMAB comparable to ... Nature Medicine Reports Elimination of Large Tumors in Mice by Messenger RNA-Encoded Bispecific Antibodies * ...

https://pipelinereview.com/index.php/2017061364945/DNA-RNA-and-Cells/Nature-Medicine-Reports-Elimination-of-Large-Tumors-in-Mice-by-Messenger-RNA-Encoded-Bispecific-Antibodies.html

... May 22, 2023. Megan ... 1 The bispecific antibody was granted accelerated approval for patients with multiple myeloma who have already undergone 4 ... Catamero: The MajesTEC-1 trial was a pivotal clinical trial that led to the FDA approval for teclistamab-a monoclonal antibody ... but you do not ever want to assume that its an AE from the bispecific [because] you do not want to miss an infection. In ...

https://www.oncnursingnews.com/view/early-intervention-is-key-in-managing-crs-for-patients-with-multiple-myeloma-receiving-teclistamab

Roche Bi-Specific Antibody Has Eylea In Its Sights After Lucentis Win. * 12 Feb 2018. ... Subject: Roche Bi-Specific Antibody Has Eylea In Its Sights After Lucentis Win ...

https://scrip.pharmaintelligence.informa.com/SC100382/Roche-Bi-Specific-Antibody-Has-Eylea-In-Its-Sights-After-Lucentis-Win

Antibodies, Bispecific -- therapeutic use. Antibodies, Monoclonal -- therapeutic use. Hemophilia A -- drug therapy. Antibodies ... Start Over You searched for: Subjects Antibodies, Bispecific -- adverse effects ✖Remove constraint Subjects: Antibodies, ... Bispecific -- adverse effects. Antibodies, Monoclonal -- adverse effects. Cost-Benefit Analysis. Treatment Outcome. Humans. ... Antibodies, Bispecific -- adverse effects✖[remove]1. *Antibodies, Bispecific -- therapeutic use1. *Antibodies, Monoclonal -- ...

https://collections.nlm.nih.gov/?f%5Bdrep2.subjectAggregate%5D%5B%5D=Antibodies%2C+Bispecific+--+adverse+effects

CD3; EGFR; HER3; MET; T-cell retargeting; bispecific antibody; dual targeting; hetEHD2; heterodimerization; light chain problem ... Bispecific antibodies have emerged as therapeutic molecules with a multitude of modes of action and applications. Here, we ... The eIg technology to generate Ig-like bispecific antibodies. Kühl, Lennart; Aschmoneit, Nadine; Kontermann, Roland E; Seifert ... In summary, we established the eIg technology as a versatile and robust platform for the generation of bispecific antibodies of ...

https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-35427197

NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies. 2 February 2023. 12 ... The post NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies appeared ...

https://www.podplay.com/en-gb/podcasts/vjhemonc-podcast-176853/episodes/nhl-highlights-at-ash-2022-updates-in-mcl-the-role-of-transplantation-and-novel-bispecific-antibodies-128134737

What is a monoclonal antibody and how is it used to treat cancer? Learn more here. ... Bispecific monoclonal antibodies. These drugs are made up of parts of 2 different mAbs, meaning they can attach to 2 different ... An antibody is a protein that sticks to a specific protein called an antigen. Antibodies circulate throughout the body until ... Naked monoclonal antibodies. Naked mAbs are antibodies that have no drug or radioactive material attached to them. They work by ...

https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/monoclonal-antibodies.html

Awarded SBIR Funding for Systemic Pre-targeted Radioimmunothearpy with Bispecific Single Domain Antibodies for Cancer Treatment ... Awarded SBIR Funding for Systemic Pre-targeted Radioimmunothearpy with Bispecific Single Domain Antibodies for Cancer Treatment ... supports the academic, biopharma, and diagnostic industries with antibodies and antibody based tools used in basic research, ... to develop bispecific single chain recombinant antibodies for pre-targeted cancer diagnostic imaging and treatment. The funds ...

https://www.nsmedicaldevices.com/pressreleases/rockland-immunochemicals-inc-awarded-sbir-funding-for-systemic-pre-targeted-radioimmunothearpy-with-bispecific-single-domain-antibodies-for-cancer-treatment/

ProMab will be hosting a webinar encompassing our Bispecific Antibody ... Interested in learning more about Bispecific Antibody Engineering? ... ProMab Bispecific Antibody Webinar. Interested in learning more about Bispecific Antibody Engineering? ProMab will be hosting a ... webinar encompassing our Bispecific Antibody Engineering platform, helping researchers bring personalized medicine closer to ...

https://www.promab.com/blogs/promab-bispecific-antibody-webinar

Bispecific Antibody Congress, August 20-22, 2019 Washington, DC Bispecific antibodies continue to show significant and ... While the development of bispecific antibodies is an evolving field, many challenges are still awaiting to be solved by experts ... Bispecific Antibody Congress, August 20-22, 2019. Washington, DC. Bispecific antibodies continue to show significant and ... This second annual Bispecific Antibody Design conference will delve directly into the technical challenges of bispecific ...

https://fcslaboratory.com/bispecific-antibodies-pipeline-congress/

Based on whether they are mono-specific or bi-specific and where they bind to the SARS-CoV-2 virus, these antibodies can be ... Antibody therapeutics have great importance for advanced cases of SARS-CoV-2 where a vaccine would not be effective and may be ... Crucially, these antibodies effectively neutralize the emerging B.1.1.7 and B.1.351 SARS-CoV-2 variants of concern.. These ... Scientists at NIAID have developed recombinant monoclonal antibodies that are effective in vitro and in vivo at neutralizing ...

http://www.techtransfer.nih.gov/tech/tab-3448

F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their ... F-star is the only biotechnology company able to create bispecific antibodies where the second binding site is in the constant ... F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their ... offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products. ...

https://biopharmaspec.com/case-studies/f-star-biotechnology-ltd-peptide-mapping-of-bispecific-antibody-products/

Bispecific Antibody CMC. Efficient production of bispecific antibodies-optimization of transfection strategy leads to high- ... Articles from Antibody Therapeutics are provided here courtesy of Oxford University Press ... Special Issue: Artificial Intelligence in antibody discovery, development and beyond. AB-Amy: machine learning aided ... Alpaca single B cell interrogation and heavy-chain-only antibody discovery on an optofluidic platform ...

https://ncbi.nlm.nih.gov/pmc/journals/3990/latest/

Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. In: Blood ... Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood ... Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. / Meermeier ... BCMA-CD3-targeting bispecific antibodies (BsAb) are a recently developed immunotherapy class which shows potent tumor killing ...

https://mayoclinic.pure.elsevier.com/en/publications/tumor-burden-limits-bispecific-antibody-efficacy-through-t-cell-e-2

We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+ T cell/myeloma cell ... Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for ... Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for ...

https://cima.cun.es/en/research/scientific-activity/scientific-publications/target-expression-generation-preclinical-activity-pharmacokinetics-bcma-t-cell-bispecific-antibody-multiple-myeloma-treatment

Immunotherapy with CD19-targeting bispecific T-cell engagers (CD19BiTEs) has demonstrated highly effective killing of cancer ... A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells. 28 November 2018 ... Lejeune M, Kose MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. ... Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol. 2015;33:1079-86. ...

https://www.nature.com/articles/s41408-022-00634-4?error=cookies_not_supported

Five months after the first anti-CD20xCD3 T-cell engaging bispecific antibody, Roche Holding AGs Lunsumio (mosunetuzumab), ... data on Merus NVs bispecific antibody MCLA-128 for the treatment of patients with NRG-1 gene fusions at the AACR-NCI-EORTC ... Genmab, Abbvie to join Roche with FDA nod for CD20 bispecific in lymphoma. BioWorld ...

https://www.bioworld.com/articles/topic/153-clinical-bioworld-medtech?page=270

To overcome this off-target resistance, bispecific antibodies (bsAbs) were developed to simultaneously target differential ... Targeted therapy also includes the use of monoclonal antibodies (mAbs). These drugs recognize specific oncogenic proteins ... 1. Introduction: From Monoclonal Antibodies to Bispecific Antibodies. In the last two decades, monoclonal antibody (mAb)-based ... a HER2-Targeted Bispecific Antibody) in Combination with KN046 (an Anti-PD-L1/CTLA-4 Bispecific Antibody) in Patients (Pts) ...

https://www2.mdpi.com/1999-4923/14/11/2442

FDA Approves New Bispecific Antibody for Non-Hodgkin Lymphoma Subtype. May 31, 2023 ...

https://www.lls.org/news/leukemia-lymphoma-society-launches-first-its-kind-global-master-clinical-trial-pediatric-acute

Affimeds AFM13 is a proprietary bispecific antibody designed to bind to CD16a on NK cells and CD30 on lymphoma cells. Initial ... Kerbauy, L.N., et al. (2021) Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK ... NK cells combined with bispecific antibody display potent anti-tumor activity against lymphoma cells. ... NK cells combined with bispecific antibody display potent anti-tumor activity against lymphoma cells. ...

https://medicalnewsupdates.com/nk-cells-combined-with-bispecific-antibody-display-potent-anti-tumor-activity-against-lymphoma-cells/

Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer. / Sewnath, CAN; Behrens, LM; van Egmond ... Sewnath, CAN., Behrens, LM., & van Egmond, M. (2022). Targeting myeloid cells with bispecific antibodies as novel ... Sewnath, CAN, Behrens, LM & van Egmond, M 2022, Targeting myeloid cells with bispecific antibodies as novel immunotherapies of ... N2 - Introduction: Most bispecific antibody (BsAb) therapies focus on stimulating the adaptive immune system, in particular T ...

https://research.vumc.nl/en/publications/targeting-myeloid-cells-with-bispecific-antibodies-as-novel-immun

New Bispecific Antibody Demonstrates Clinical Activity in Patients With Multiple Myeloma. April 17, 2023 ...

https://www.aacr.org/about-the-aacr/newsroom/news-releases/

Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma. Saturday, Dec ... Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Immune Signaling and Antibody-Therapeutic Targeting in Myeloid ...

https://www.ucsf.edu/news/2022/12/424416/international-hematologic-conference-features-ucsf-health-experts

ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody ... WuXi Biologics, ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody. 28 December 2021 ... Chris Chen, CEO of WuXi Biologics, commented, "We are glad to partner with ImmuneOncia to proceed its first bispecific antibody ... ImmuneOncias therapeutic bispecific antibody targeting PD-L1 and CD47. ...

https://biopharmaapac.com/news/28/1117/wuxi-biologics-immuneoncia-sign-mou-for-development-and-manufacturing-of-anti-pd-l1-cd47-bispecific-antibody.html

The MajesTEC-1 trial was a pivotal clinical trial that led to the FDA approval for teclistamab-a monoclonal antibody that targets the CD3 receptor on the T-cell and then the BCMA receptor on the myeloma cell. (oncnursingnews.com)
To make a monoclonal antibody, researchers first have to identify the right antigen to attack. (cancer.org)
Recombinant humanized IgG1-kappa isotype monoclonal antibody fragment designed for intraocular use. (medscape.com)
Ublituximab is a CD20-directed monoclonal antibody indicated for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. (medscape.com)

Merus, which develops bispecific antibody therapeutics to treat cancer patients, and Selexis, which has technologies for biologics drug discovery and Research Cell Bank (RCB) development, received a EUREKA Eurostars grant of €2.1 million (USD 2.33 million) to develop bispecific antibody combination products for the treatment of colorectal cancer, the companies announced on May 20, 2015. (pharmtech.com)
Utrecht, The Netherlands and Villejuif, France - Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, today announced entry into a strategic collaboration to jointly develop bispecific antibodies for therapeutic immuno-oncology applications. (baycitycapital.com)
November 14th, 2016 - Rockland Immunochemicals, Inc. (Rockland) announced today the award of a $299,625 Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) to develop bispecific single chain recombinant antibodies for pre-targeted cancer diagnostic imaging and treatment. (nsmedicaldevices.com)

With the best-in-class RCB generation capabilities of Selexis on board, the existing knowledge and infrastructure for the manufacturing of therapeutic monoclonal antibodies is optimally leveraged. (pharmtech.com)
Under the terms of the agreement, Merus and Gustave Roussy will collaborate on the design and conduct of basic, preclinical and translational research studies and early clinical studies leveraging Merus' portfolio of therapeutic human bispecific antibody candidates, including bispecific antibodies in pre-clinical development targeting combinations of immunomodulatory molecules. (baycitycapital.com)
Our alliance with Merus illustrates our strategic commitment, as one of the leading Comprehensive Cancer Centres in Europe, to actively collaborate with biotech companies developing innovative therapeutic antibodies and biotechnological platforms in the field of precision medicine and immunotherapy," said Professor Alexander Eggermont, General Director of Gustave Roussy. (baycitycapital.com)
Administering the mRNA encoding the bispecific antibody, thus enabling the patient's body to synthesize the therapeutic protein, may profoundly reduce complexity of drug development. (pipelinereview.com)
To demonstrate universality of this novel approach, bispecific RiboMABs targeting different tumor antigens were generated, and their therapeutic potency was tested in mice bearing human tumors and repopulated with human immune cells. (pipelinereview.com)
Bispecific antibodies have emerged as therapeutic molecules with a multitude of modes of action and applications. (bvsalud.org)
Bispecific antibodies continue to show significant and impressive therapeutic value. (fcslaboratory.com)
WuXi Biologics ('WuXi Bio') (2269.HK), a global company with leading open-access biologics technology platforms, and ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia's therapeutic bispecific antibody targeting PD-L1 and CD47. (biopharmaapac.com)
23. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies. (nih.gov)

About Merus B.V. Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. (baycitycapital.com)
Antibody therapeutics have great importance for advanced cases of SARS-CoV-2 where a vaccine would not be effective and may be more effective than a vaccine in certain high-risk populations. (nih.gov)
These recombinant monoclonal antibodies can be used alone, in combination, or with other therapeutics for the treatment of SARS-COV-2. (nih.gov)
In addition to their potential as therapeutics, these antibodies against SARS-CoV-2 can be used as prophylactics and in assay development. (nih.gov)
29. Bispecific antibody based therapeutics: Strengths and challenges. (nih.gov)
32. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology]. (nih.gov)

Recent advances in the generation of bispecific antibodies for tumor immunotherapy. (nih.gov)
Bispecific antibodies act by connecting human immune cells to tumor cells for highly efficient killing and have demonstrated great promise as immunotherapy agents. (pipelinereview.com)
Using radiolabeled antibodies, PRIT combines the advantages of radiation's cytotoxic potential with the specificity of tumor-targeting agents. (nsmedicaldevices.com)
In most cases, tumor-targeting agents are radiolabeled antibodies, which can be used for the diagnosis, detection, and therapy of cancer. (nsmedicaldevices.com)
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center. (medicalnewsupdates.com)
Introduction: Most bispecific antibody (BsAb) therapies focus on stimulating the adaptive immune system, in particular T cells, to promote tumor cell killing. (vumc.nl)
21. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. (nih.gov)

But other monoclonal antibodies act like immunotherapy because they make the immune system respond better to allow the body to find and attack cancer cells more effectively. (cancer.org)
Immunotherapy with CD19-targeting bispecific T-cell engagers (CD19BiTEs) has demonstrated highly effective killing of cancer cells in patients with precursor acute lymphoblastic leukemia and non-Hodgkin's lymphomas. (nature.com)
25. Recombinant bispecific antibodies for cellular cancer immunotherapy. (nih.gov)
26. Bispecific antibodies for cancer immunotherapy: Current perspectives. (nih.gov)
33. Bispecific antibody platforms for cancer immunotherapy. (nih.gov)
35. Immunotherapy with bispecific antibodies. (nih.gov)

The company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including Biclonics designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1. (baycitycapital.com)
Affimed's AFM13 is a proprietary bispecific antibody designed to bind to CD16a on NK cells and CD30 on lymphoma cells. (medicalnewsupdates.com)

Recombinant bispecific antibodies for cancer therapy. (nih.gov)
Scientists at NIAID have developed recombinant monoclonal antibodies that are effective in vitro and in vivo at neutralizing SARS-CoV-2. (nih.gov)
We describe a modified and improved recombinant envelope domain III-based serologic assay for detecting ZIKV type-specific antibodies in regions with endemic DENV transmission. (cdc.gov)

Gustave Roussy's outstanding preclinical and clinical oncology teams, coupled with Merus' bispecific antibody pipeline, create a powerful research platform capable of identifying important advancements in the area of immuno-oncology. (baycitycapital.com)
We are excited to expand our opportunities for collaboration in the development of bispecific antibodies for immuno-oncology," said Professor Jean-Charles Soria, head of the Drug Development Department (DITEP) at Gustave Roussy. (baycitycapital.com)
F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. (biopharmaspec.com)

FcγR and FcαRI) to induce antibody-dependent cellular phagocytosis (ADCP) by macrophages or trogoptosis via neutrophils, as well as BsAbs that interfere with checkpoint inhibition, including the SIRPα-CD47 pathway. (vumc.nl)

In addition, Gustave Roussy will participate in clinical studies of Merus' MCLA-128, a HER2xHER3 bispecific antibody candidate that is designed for the treatment of patients with HER2-expressing solid tumors, and Merus' MCLA-117, a CLEC12AxCD3 bispecific antibody candidate that is designed to recruit and activate T-cells for the treatment of patients with acute myeloid leukemia. (baycitycapital.com)
Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. (baycitycapital.com)
Weekly application of any of the bispecific RiboMAB, directed against cancer antigens that are present in many human cancers, resulted in elimination of aggressively growing, large tumors. (pipelinereview.com)
MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors. (cancer-research-network.com)

However, the efficiency of mAbs is far from optimal, and antibody engineering is actively used to improve the molecules. (nih.gov)
The efficacy of the AHP in binding IgG anti-dsDNA antibodies to E was demonstrated in a sensitive and quantitative assay, based on the time resolved fluorescence properties of europium-labeled anti-human IgG mAbs used to probe the E. We also used this assay to screen SLE patient and normal plasmas for levels of anti-dsDNA IgG. (nih.gov)
These are known as monoclonal antibodies (mAbs or Moabs). (cancer.org)
Naked mAbs are antibodies that have no drug or radioactive material attached to them. (cancer.org)

Effects of immuno-related gene polymorphisms on a bispecific antibody targeting colorectal cancer cell. (cdc.gov)

2021) Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies. (medicalnewsupdates.com)

37. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition. (nih.gov)

Amivantamab is a bispecific antibody that targets EGFR and mesenchymal-epithelial transition factor pathways. (medpagetoday.com)
In the program, Merus and Selexis will combine their unique and proprietary Oligoclonics and SUREtechnology platforms, respectively, to develop a product combining two, bispecific, full-length immunoglobulin G antibodies that simultaneously targets and potently inhibits three receptor tyrosine kinases. (pharmtech.com)
While the development of bispecific antibodies is an evolving field, many challenges are still awaiting to be solved by experts in the field including target selection, better understanding of their mechanism of action, along with the combination selection of targets. (fcslaboratory.com)
Furthermore, the specific antibody sequences and targets will inform vaccine development and establishment of long-term immunity. (nih.gov)
BOSTON Researchers from Memorial Sloan-Kettering Cancer Center presented encouraging, though very early, data on Merus NV's bispecific antibody MCLA-128 for the treatment of patients with NRG-1 gene fusions at the AACR-NCI-EORTC Molecular Targets meeting on Sunday. (bioworld.com)

Our data show that with low doses of mRNA encoding a bispecific antibody, we get sustained production of RiboMAB comparable to those of naturally produced immunoglobulin proteins and capable of curing advanced cancers in mice," said Prof. Ugur Sahin, founder and CEO of BioNTech, who led the study. (pipelinereview.com)
Formats included bivalent bispecific IgG -like molecules (eIgs) and Fc-less Fab-eFab fusion proteins , as well as tri- and tetravalent Fab-eIg fusion proteins . (bvsalud.org)
All proteins , including bispecific antibodies for dual receptor targeting and for retargeting of T cells , efficiently assembled into functional molecules. (bvsalud.org)
Monoclonal antibodies are man-made proteins that act like human antibodies in the immune system. (cancer.org)

With our optimized off-the-shelf CHO media and feeds, we will maximize expression of the bispecific antibody combinations generated from Merus' Oligoclonics platform. (pharmtech.com)
Merus' second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia, and Merus expects to initiate clinical trials of this candidate in the first quarter of 2016. (baycitycapital.com)

Because of their ability to simultaneously bind two different antigens, bispecific antibodies are unique, and their wide potential as targeting reagents has been demonstrated over the years. (nih.gov)

Our studies indicated that this AHP could bind anti-dsDNA antibodies to E and facilitate clearance of these autoantibodies from the circulation of a monkey without E destruction. (nih.gov)
Based on whether they are mono-specific or bi-specific and where they bind to the SARS-CoV-2 virus, these antibodies can be subdivided into four groups that target (A) the receptor-binding-domain (RBD) of the SARS-COV-2 spike protein, (B) the N-terminal domain (NTD) of the SARS-COV-2 spike protein, (C) dual locations on the RBD, or (D) both the RBD and NTD. (nih.gov)

1 The bispecific antibody was granted accelerated approval for patients with multiple myeloma who have already undergone 4 prior lines of therapy, in October 2022. (oncnursingnews.com)
Sewnath, CAN , Behrens, LM & van Egmond, M 2022, ' Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer ', Expert Opinion on Biological Therapy , vol. 22, no. 8, pp. 983-995. (vumc.nl)

This second annual Bispecific Antibody Design conference will delve directly into the technical challenges of bispecific development to improve your candidates' translatability into the clinic. (fcslaboratory.com)
Identification of vaccine candidates which elicit protective antibodies against SARS-CoV-2 infections. (nih.gov)

EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (nih.gov)

Bispecific T-cell engagers (BiTEs) are novel immunotherapeutic molecules that consist of an anti-CD3 single-chain variable fragment (scFv) fused to the scFv targeting antitumor-associated antigen via a flexible linker. (nature.com)

39. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions. (nih.gov)

Biclonics are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. (baycitycapital.com)
This is the first preclinical study to demonstrate in vivo application of mRNA-encoded antibodies for successful treatment of cancer. (pipelinereview.com)
Rockland Immunochemicals, Inc. supports the academic, biopharma, and diagnostic industries with antibodies and antibody based tools used in basic research, assay development, and preclinical studies. (nsmedicaldevices.com)

Broadly neutralizing antibodies target the coronavirus fusion peptide. (nih.gov)

Previously we reported the development of an antigen based heteropolymer (AHP), a bispecific complex prepared by using the avidin-biotin system to crosslink dsDNA to a mAb specific for the human erythrocyte (E) complement receptor. (nih.gov)
An antibody is a protein that sticks to a specific protein called an antigen . (cancer.org)
Antibodies circulate throughout the body until they find and attach to the antigen. (cancer.org)
Researchers can design antibodies that specifically target a certain antigen, such as one found on cancer cells. (cancer.org)
Most serologic assays for flaviviruses measure antibodies binding to viral-envelope glycoprotein (E protein) because this antigen is a major target of human antibodies. (cdc.gov)

Here, we present a novel approach to solve the light -chain problem for the generation of bispecific Ig-like antibodies using the second constant domain of IgE (EHD2) genetically modified to force heterodimerization. (bvsalud.org)

Intravenously injecting a few micrograms of mRNA resulted in bispecific RiboMAB production in the liver cells that rapidly secreted into the circulation, reaching peak level within hours and remaining at therapeutically effective plasma concentrations for a week. (pipelinereview.com)
This Funding Opportunity Announcement (FOA) encourages applications to support the optimization of monoclonal antibodies (mAb) or mAb derivatives that recognize and eliminate cells comprising the HIV reservoir. (nih.gov)
It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (bvsalud.org)

Bispecific antibody combinations have potency and targeting advantages that provide the basis for improved anti-cancer therapies. (pharmtech.com)
Antibodies, CAR therapies, and synthetic inhibitors are being used to target B7-H3. (cancer-research-network.com)

34. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade. (nih.gov)

27. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture. (nih.gov)

Rockland received the award because of its strong scientific team and long track record of success in development of antibody reagents for diagnostics and cancer research with the NCI and other major research institutions. (nsmedicaldevices.com)
Their Modular Antibody Technology™ platform, offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products. (biopharmaspec.com)
Dr. Chris Chen , CEO of WuXi Biologics, commented, "We are glad to partner with ImmuneOncia to proceed its first bispecific antibody into clinical development through our integrated services and know-how. (biopharmaapac.com)
At WuXi Biologics, we have demonstrated our extensive capabilities for CMC development, analytical method, and quality control by enabling over 60 bispecific projects. (biopharmaapac.com)
In lay terms, can you describe the premise of your study that is looking at the development of neutralizing antibodies against SARS-CoV-2? (nih.gov)

Crucially, these antibodies effectively neutralize the emerging B.1.1.7 and B.1.351 SARS-CoV-2 variants of concern. (nih.gov)
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. (nih.gov)

One way the body's immune system attacks foreign substances is by making large numbers of antibodies. (cancer.org)

38. Current status and future perspectives of bispecific antibodies in the treatment of lung cancer. (nih.gov)
Bispecific antibody for treatment of adults with neovascular (wet) age-related macular degeneration. (medscape.com)

40. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. (nih.gov)

It has very different advantages that maybe other neutralizing antibodies may not have, and we think we want to contribute to this global research using our unique technologies and expertise. (nih.gov)

ProMab will be hosting a webinar encompassing our Bispecific Antibody Engineering platform, helping researchers bring personalized medicine closer to reality. (promab.com)

We previously described a serologic assay using domain III of the ZIKV E protein (EDIII) to detect ZIKV type-specific antibodies among persons in areas with DENV and ZIKV cocirculation ( 19 ). (cdc.gov)

In Nature Medicine, BioNTech presents the application of this technology for mRNA-based in vivo delivery of T cell engaging bispecific antibodies. (pipelinereview.com)

NOTE: Some m onoclonal antibodies used to treat cancer are referred to as targeted therapy because they have a specific target on a cancer cell that they aim to find, attach to, and attack. (cancer.org)
We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+ T cell/myeloma cell crosslinking, followed by CD4+/CD8+ T cell activation, and secretion of interferon-γ, granzyme B, and perforin. (cun.es)
22. Bispecific antibodies for immune cell retargeting against cancer. (nih.gov)

High avidity anti-dsDNA IgG antibodies are believed to play an important role in the pathogenesis of the autoimmune disease systemic lupus erythematosus (SLE) and therefore attempts have been made to reduce the concentration of these antibodies in the bloodstream of SLE patients. (nih.gov)

Anatomy10

Organisms7

Diseases3

Chemicals and Drugs71

Analytical, Diagnostic and Therapeutic Techniques and Equipment33

Phenomena and Processes23

Disciplines and Occupations1

Information Science3

Health Care3

Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. (1/429)

Dual specificity antibodies using a double-stranded oligonucleotide bridge. (2/429)

An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules. (3/429)

Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. (4/429)

Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. (5/429)

Expression and characterization of bispecific single-chain Fv fragments produced in transgenic plants. (6/429)

Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. (7/429)

Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. (8/429)

Antibodies, Bispecific

Antibodies

Antibody Specificity

Antibodies, Monoclonal

Antibodies, Viral

Antibodies, Bacterial

Single-Chain Antibodies

Antibody Affinity

Antibody Formation

Antibodies, Neutralizing

Binding Sites, Antibody

Antibodies, Anti-Idiotypic

Antigens, CD3

Immunoglobulin Fragments

Fluorescent Antibody Technique

Antibodies, Neoplasm

Haptens

Immunoglobulin Fab Fragments

Epitopes

HIV Antibodies

Antibodies, Protozoan

Antibody-Dependent Cell Cytotoxicity

Antibodies, Antinuclear

Cross Reactions

Radioimmunotherapy

Immunoglobulin G

Hybridomas

Radioimmunodetection

Immunotherapy

Molecular Sequence Data

Immunotoxins

Receptors, IgG

Mice, Inbred BALB C

Antigen-Antibody Reactions

Pentetic Acid

Antigens, CD19

Amino Acid Sequence

Protein Engineering

Sialic Acid Binding Ig-like Lectin 2

Immunoglobulin M

Antigens, Neoplasm

Autoantibodies

Antibodies, Fungal

Carcinoembryonic Antigen

Single-Domain Antibodies

Antigen-Antibody Complex

Immunoglobulin Variable Region

Neutralization Tests

T-Lymphocytes

Cytotoxicity, Immunologic

Antigens, CD20

Indium Radioisotopes

Antibodies, Monoclonal, Humanized

Enzyme-Linked Immunosorbent Assay

Recombinant Proteins

Tumor Cells, Cultured

Antibodies, Blocking

Recombinant Fusion Proteins

Immunization, Passive

Cell Line

Mice, Nude

Antibodies, Heterophile

Antibodies, Catalytic

Rabbits

Cell Line, Tumor

Lymphocyte Activation

Immunoglobulin Fc Fragments

Leukemia, B-Cell

Tissue Distribution

Neoplasm Transplantation

Iodine Radioisotopes

Mice, SCID

Immunization

Lymphoma, B-Cell

Antigens

Antigens, CD

Flow Cytometry

Heterocyclic Compounds, 1-Ring

Immunoglobulin A

Fluorescent Antibody Technique, Indirect